• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

艾迪注射液联合吉西他滨为基础的化疗治疗晚期非小细胞肺癌的系统评价和荟萃分析。

Aidi injection as adjunctive treatment to gemcitabine-based chemotherapy for advanced non-small cell lung cancer: a systematic review and meta-analysis.

机构信息

Department of Pharmacy, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China.

出版信息

Pharm Biol. 2021 Dec;59(1):1260-1275. doi: 10.1080/13880209.2021.1973038.

DOI:10.1080/13880209.2021.1973038
PMID:34541998
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8451693/
Abstract

CONTEXT

Aidi injection is one of the most commonly use antitumor Chinese medicine injections for advanced non-small cell lung cancer (NSCLC). It is made from the extraction of , and

OBJECTIVE

To evaluate the efficacy and safety of Aidi injection in combination with gemcitabine-based chemotherapy (GBC) for advanced NSCLC.

MATERIALS AND METHODS

PubMed, Embase, Cochrane Library, Chinese Biological Medicine, China National Knowledge Infrastructure, Wanfang, and VIP were searched for relevant randomised controlled trials (RCTs) comparing Aidi injection plus GBC treatment with GBC alone in NSCLC, from inception up to October 2020. The primary outcomes were objective response rate (ORR), and disease control rate (DCR). Secondary outcomes were quality of life (QOL) and adverse drug reactions (ADRs). The quality of evidence was rated using the GRADE approach. This study was registered with PROSPERO: CRD42021221225.

RESULTS

In total, 54 RCTs involving 4318 NSCLC patients were included in this meta-analysis. Compared with GBC alone, Aidi injection plus GBC significantly improve ORR (risk ratios [RR] = 1.38, 95% confidence interval [CI] 1.29-1.48), DCR (RR = 1.15, 95% CI 1.12-1.19), QOL (RR = 1.71, 95% CI 1.54-1.89), and reduced the risk of gastrointestinal toxicity, thrombocytopenia, neutropenia, liver injury, renal injury, and anaemia. The evaluation results of the evidence ranged from moderate to low.

CONCLUSIONS

Current moderate evidence revealed that Aidi injection as an adjunctive treatment to GBC was associated with superior benefits in patients with advanced NSCLC and alleviate toxicities. High-quality RCTs are needed to further confirm the results.

摘要

背景

艾迪注射液是晚期非小细胞肺癌（NSCLC）最常用的抗肿瘤中药注射液之一。它是从 和 的提取物制成的。

目的

评估艾迪注射液联合吉西他滨为基础的化疗（GBC）治疗晚期 NSCLC 的疗效和安全性。

材料和方法

检索了 PubMed、Embase、Cochrane 图书馆、中国生物医学文献数据库、中国国家知识基础设施、万方和 VIP，以获取比较艾迪注射液联合 GBC 治疗与单独 GBC 治疗 NSCLC 的相关随机对照试验（RCTs），检索时间截至 2020 年 10 月。主要结局指标是客观缓解率（ORR）和疾病控制率（DCR）。次要结局指标是生活质量（QOL）和不良反应（ADRs）。使用 GRADE 方法评价证据质量。本研究已在 PROSPERO 注册：CRD42021221225。

结果

共纳入 54 项 RCT，涉及 4318 例 NSCLC 患者。与单独 GBC 相比，艾迪注射液联合 GBC 可显著提高 ORR（风险比 [RR] = 1.38，95%置信区间 [CI] 1.29-1.48）、DCR（RR = 1.15，95% CI 1.12-1.19）、QOL（RR = 1.71，95% CI 1.54-1.89），并降低胃肠道毒性、血小板减少症、中性粒细胞减少症、肝损伤、肾损伤和贫血的风险。证据评估结果为中等到低。

结论

目前的中等证据表明，艾迪注射液作为 GBC 的辅助治疗，与晚期 NSCLC 患者的优势相关，并减轻毒性。需要高质量的 RCT 进一步证实这些结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cda/8451693/806c69e254b9/IPHB_A_1973038_F0009_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cda/8451693/3a87cb668334/IPHB_A_1973038_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cda/8451693/3d1e18b71b5d/IPHB_A_1973038_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cda/8451693/d34e44696794/IPHB_A_1973038_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cda/8451693/58b7a76b28b3/IPHB_A_1973038_F0004_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cda/8451693/3cec99059130/IPHB_A_1973038_F0005_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cda/8451693/8b4b54fa3f1f/IPHB_A_1973038_F0006_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cda/8451693/8862ed798dc2/IPHB_A_1973038_F0007_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cda/8451693/7cd1e04a3df3/IPHB_A_1973038_F0008_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cda/8451693/806c69e254b9/IPHB_A_1973038_F0009_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cda/8451693/3a87cb668334/IPHB_A_1973038_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cda/8451693/3d1e18b71b5d/IPHB_A_1973038_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cda/8451693/d34e44696794/IPHB_A_1973038_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cda/8451693/58b7a76b28b3/IPHB_A_1973038_F0004_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cda/8451693/3cec99059130/IPHB_A_1973038_F0005_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cda/8451693/8b4b54fa3f1f/IPHB_A_1973038_F0006_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cda/8451693/8862ed798dc2/IPHB_A_1973038_F0007_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cda/8451693/7cd1e04a3df3/IPHB_A_1973038_F0008_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cda/8451693/806c69e254b9/IPHB_A_1973038_F0009_C.jpg

相似文献

1
Aidi injection as adjunctive treatment to gemcitabine-based chemotherapy for advanced non-small cell lung cancer: a systematic review and meta-analysis.艾迪注射液联合吉西他滨为基础的化疗治疗晚期非小细胞肺癌的系统评价和荟萃分析。
Pharm Biol. 2021 Dec;59(1):1260-1275. doi: 10.1080/13880209.2021.1973038.
2
Clinical efficacy and safety of Aidi injection plus paclitaxel-based chemotherapy for advanced non-small cell lung cancer: A meta-analysis of 31 randomized controlled trials following the PRISMA guidelines.艾迪注射液联合紫杉醇类化疗治疗晚期非小细胞肺癌的临床疗效和安全性的 Meta 分析：按照 PRISMA 指南的 31 项随机对照试验。
J Ethnopharmacol. 2019 Jan 10;228:110-122. doi: 10.1016/j.jep.2018.09.024. Epub 2018 Sep 20.
3
Aidi injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: A meta-analysis of 42 RCTs following the PRISMA guidelines.艾迪注射液联合铂类化疗方案治疗ⅢB/Ⅳ期非小细胞肺癌的 Meta 分析：遵循 PRISMA 指南的 42 项 RCT 研究的汇总分析。
J Ethnopharmacol. 2018 Jul 15;221:137-150. doi: 10.1016/j.jep.2018.04.013. Epub 2018 Apr 12.
4
Has aidi injection the attenuation and synergistic efficacy to gemcitabine and cisplatin in non-small cell lung cancer? A meta-analysis of 36 randomized controlled trials.艾迪注射液对吉西他滨和顺铂治疗非小细胞肺癌是否具有减毒增效作用？一项纳入36项随机对照试验的荟萃分析。
Oncotarget. 2017 Jan 3;8(1):1329-1342. doi: 10.18632/oncotarget.13617.
5
Can Aidi injection restore cellular immunity and improve clinical efficacy in non-small-cell lung cancer patients treated with platinum-based chemotherapy? A meta-analysis of 17 randomized controlled trials following the PRISMA guidelines.艾迪注射液能否恢复细胞免疫并提高接受铂类化疗的非小细胞肺癌患者的临床疗效？一项遵循PRISMA指南的17项随机对照试验的荟萃分析。
Medicine (Baltimore). 2016 Nov;95(44):e5210. doi: 10.1097/MD.0000000000005210.
6
Clinical efficacy and safety of Huachansu injection combination with platinum-based chemotherapy for advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials.华蟾素注射液联合铂类化疗治疗晚期非小细胞肺癌的临床疗效及安全性的系统评价和 Meta 分析。
Medicine (Baltimore). 2021 Sep 10;100(36):e27161. doi: 10.1097/MD.0000000000027161.
7
Clinical efficacy and safety of aidi injection combination with vinorelbine and cisplatin for advanced non-small-cell lung carcinoma: A systematic review and meta-analysis of 54 randomized controlled trials.艾迪注射液联合长春瑞滨和顺铂治疗晚期非小细胞肺癌的临床疗效和安全性：54 项随机对照试验的系统评价和荟萃分析。
Pharmacol Res. 2020 Mar;153:104637. doi: 10.1016/j.phrs.2020.104637. Epub 2020 Jan 11.
8
Can Aidi injection improve overall survival in patients with non-small cell lung cancer? A systematic review and meta-analysis of 25 randomized controlled trials.艾迪注射液能否提高非小细胞肺癌患者的总生存期？25 项随机对照试验的系统评价和荟萃分析。
Complement Ther Med. 2018 Apr;37:50-60. doi: 10.1016/j.ctim.2018.01.011. Epub 2018 Jan 31.
9
Efficacy and safety of Shenqi Fuzheng injection combined with platinum-based chemotherapy for stage III/IV non-small cell lung cancer: A protocol for systematic review and meta-analysis of randomized controlled trials.参芪扶正注射液联合铂类化疗治疗Ⅲ/Ⅳ期非小细胞肺癌的疗效与安全性：一项随机对照试验的系统评价与Meta分析方案
Medicine (Baltimore). 2019 Sep;98(39):e17350. doi: 10.1097/MD.0000000000017350.
10
Assessment on the Efficacy and Safety of Aidi Injection Combined with Vinorelbine and Cisplatin for Treatment of Advanced Nonsmall Cell Lung Cancer.艾迪注射液联合长春瑞滨和顺铂治疗晚期非小细胞肺癌的疗效与安全性评估
Chin Med J (Engl). 2016 Mar 20;129(6):723-30. doi: 10.4103/0366-6999.178016.

引用本文的文献

1
Herb-drug interactions in oncology: pharmacodynamic/pharmacokinetic mechanisms and risk prediction.肿瘤学中的草药-药物相互作用：药效学/药代动力学机制及风险预测
Chin Med. 2025 Jul 7;20(1):107. doi: 10.1186/s13020-025-01156-4.
2
A Phyto-mycotherapeutic Supplement, Namely , as Effective Adjuvant in Brain Cancer Management: An In Vitro Study Using U251 Human Glioblastoma Cell Line.一种植物-真菌治疗补充剂，即作为脑癌管理的有效辅助剂：使用 U251 人神经胶质瘤细胞系的体外研究。
Int J Mol Sci. 2024 Jun 5;25(11):6204. doi: 10.3390/ijms25116204.
3
Cantharidin suppresses hepatocellular carcinoma development by regulating EZH2/H3K27me3-dependent cell cycle progression and antitumour immune response.

本文引用的文献

1
Cancer statistics, 2020.癌症统计数据，2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
2
Meta-Analysis of Astragalus-Containing Traditional Chinese Medicine Combined With Chemotherapy for Colorectal Cancer: Efficacy and Safety to Tumor Response.含黄芪的中药联合化疗治疗结直肠癌的Meta分析：对肿瘤反应的疗效和安全性
Front Oncol. 2019 Aug 13;9:749. doi: 10.3389/fonc.2019.00749. eCollection 2019.
3
SphK1 functions downstream of IGF-1 to modulate IGF-1-induced EMT, migration and paclitaxel resistance of A549 cells: A preliminary in vitro study.
斑蝥素通过调节 EZH2/H3K27me3 依赖性细胞周期进程和抗肿瘤免疫反应来抑制肝癌的发展。
BMC Complement Med Ther. 2023 May 18;23(1):160. doi: 10.1186/s12906-023-03975-0.
4
Advances for pharmacological activities of - A review.β-榄香烯的药理活性研究进展。
Pharm Biol. 2023 Dec;61(1):177-188. doi: 10.1080/13880209.2022.2158349.
5
Compound Capsule Combined with Chemotherapy for Non-Small-Cell Lung Cancer: A PRISMA-Compliant Systematic Review and Meta-Analysis of Randomized Controlled Trials.复方胶囊联合化疗治疗非小细胞肺癌：一项符合PRISMA标准的随机对照试验系统评价与Meta分析
Evid Based Complement Alternat Med. 2021 Dec 16;2021:9535061. doi: 10.1155/2021/9535061. eCollection 2021.
鞘氨醇激酶1在胰岛素样生长因子-1下游发挥作用，调节胰岛素样生长因子-1诱导的A549细胞上皮-间质转化、迁移和对紫杉醇的耐药性：一项初步的体外研究。
J Cancer. 2019 Jul 10;10(18):4264-4269. doi: 10.7150/jca.32646. eCollection 2019.
4
Traditional Chinese medicine as a cancer treatment: Modern perspectives of ancient but advanced science.中医治疗癌症：古老而先进科学的现代视角。
Cancer Med. 2019 May;8(5):1958-1975. doi: 10.1002/cam4.2108. Epub 2019 Apr 3.
5
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
6
Aidi injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: A meta-analysis of 42 RCTs following the PRISMA guidelines.艾迪注射液联合铂类化疗方案治疗ⅢB/Ⅳ期非小细胞肺癌的 Meta 分析：遵循 PRISMA 指南的 42 项 RCT 研究的汇总分析。
J Ethnopharmacol. 2018 Jul 15;221:137-150. doi: 10.1016/j.jep.2018.04.013. Epub 2018 Apr 12.
7
Anti-tumour effects of polysaccharide extracted from and cell-mediated immunity.从……中提取的多糖的抗肿瘤作用及细胞介导免疫。 （你提供的原文似乎不完整，“from”后面缺少具体内容）
Exp Ther Med. 2018 Feb;15(2):1694-1701. doi: 10.3892/etm.2017.5568. Epub 2017 Nov 27.
8
Ginseng phytochemicals as therapeutics in oncology: Recent perspectives.人参植物化学成分在肿瘤学中的治疗应用：最新观点。
Biomed Pharmacother. 2018 Apr;100:52-63. doi: 10.1016/j.biopha.2018.01.155. Epub 2018 Feb 6.
9
Ginsenoside Rg3 sensitizes hypoxic lung cancer cells to cisplatin via blocking of NF-κB mediated epithelial-mesenchymal transition and stemness.人参皂苷 Rg3 通过阻断 NF-κB 介导的上皮-间充质转化和干性来增强缺氧肺癌细胞对顺铂的敏感性。
Cancer Lett. 2018 Feb 28;415:73-85. doi: 10.1016/j.canlet.2017.11.037. Epub 2017 Dec 2.
10
Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune.人参皂苷 Rg3 通过下调 PD-L1 并恢复免疫来减轻肺癌的顺铂耐药性。
Biomed Pharmacother. 2017 Dec;96:378-383. doi: 10.1016/j.biopha.2017.09.129. Epub 2017 Oct 12.